Back to top
more

Aziyo Biologics (AZYO)

(Real Time Quote from BATS)

$1.16 USD

1.16
571,914

-0.06 (-4.92%)

Updated Mar 22, 2023 03:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.52%
2Buy18.26%
3Hold9.60%
4Sell5.38%
5Strong Sell2.61%
S&P50010.68%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

ACER's Stock Down on Failure of Phase II Study, Cash Updates

by Zacks Equity Research

ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.

Catalyst's (CPRX) Q4 Earnings & Sales Top, Boosted by Firdapse

by Zacks Equity Research

Catalyst Pharmaceuticals (CPRX) reports better-than-expected financial performance as it beats both earnings and revenue estimates. Firdapse sales continue to grow year over year.

Aziyo Biologics, Inc. (AZYO) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Aziyo Biologics, Inc. (AZYO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Medical Stocks Lagging Bionano Genomics (BNGO) This Year?

by Zacks Equity Research

Here is how Bionano Genomics, Inc. (BNGO) and Aziyo Biologics, Inc. (AZYO) have performed compared to their sector so far this year.

Aziyo Biologics, Inc. (AZYO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -10.61% and 1.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sigilon Therapeutics, Inc. (SGTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of 37.21% and 73.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 0% and 60.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aziyo Biologics, Inc. (AZYO) Soars 11.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Aziyo Biologics, Inc. (AZYO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Harpoon Therapeutics, Inc. (HARP) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 3.64% and 9.95%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Brookdale Senior Living (BKD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Brookdale (BKD) delivered earnings and revenue surprises of -9.76% and 0.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of 11.11% and 2.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Aziyo Biologics (AZYO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aziyo Biologics, Inc. (AZYO) and AMN Healthcare Services (AMN) have performed compared to their sector so far this year.

Aziyo Biologics, Inc. (AZYO) Moves 7.8% Higher: Will This Strength Last?

by Zacks Equity Research

Aziyo Biologics, Inc. (AZYO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Aziyo Biologics, Inc. (AZYO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of 3.23% and 6.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -14.84% and 2.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aziyo Biologics, Inc. (AZYO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -28.13% and 2.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About Aziyo Biologics, Inc. (AZYO) Rating Upgrade to Buy

by Zacks Equity Research

Aziyo Biologics, Inc. (AZYO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Has Aziyo Biologics, Inc. (AZYO) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aziyo Biologics, Inc. (AZYO) and Doximity (DOCS) have performed compared to their sector so far this year.

PolarityTE (PTE) Gets FDA Nod to Begin Pivotal Ulcer Study

by Zacks Equity Research

PolarityTE (PTE) announces removal of clinical hold on a proposed pivotal study to evaluate its SkinTE for chronic cutaneous ulcers. PolarityTE plans to start enrollment in the next few months.

Wall Street Analysts See a 123% Upside in Aziyo Biologics, Inc. (AZYO): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 123.3% upside potential for Aziyo Biologics, Inc. (AZYO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Aziyo Biologics, Inc. (AZYO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -32.79% and -0.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Aziyo Biologics, Inc. (AZYO) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Aziyo Biologics, Inc. (AZYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.